BRAF and neoplasm: Emerging evidence indicates that the TME can be reprogrammed by targeted therapy and may actively support drug‐tolerant states.[9] While BRAF/MEKi can promote anti‐tumor immune responses,[10, 11, 12] how the TME changes during tumor regression and residual disease, and whether these changes generate barriers to effective immune surveillance, remains largely undefined.